65,437 trials
MPN (Myeloproliferative Neoplasms)
Primary: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 — 65; 1 participants — p=<0.0001
Myopia
Primary: Overall Subjective Comfort — 51.7; 51.3; 51.3 CLUE score
Myopia
Primary: Overall Comfort — 8.4 units on a scale
Myopia
Primary: Lens Centration Acceptance — 74; 62; 69; 8 eyes
Cataract
Primary: Endothelial Cell Count Change From Baseline — -7.91; -5.11; -4.92 Percent change from baseline
Type 2 Diabetes Mellitus
Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin
Stress
Primary: Stress Levels After 4 Sessions (2nd Evaluation) — 49.68; 54.69; 54.00 units on a scale — p=0.352
Essential Tremor
Primary: Modified FTM(Fahn-Tolosa-Marin) Essentials Tremor Rating Scale, Sum of All Essential Rating Tremor Scales Including Voice Tremor — 13.4; 10.8; 13.0 Points — p=0.013
Eyelash Hypotrichosis
Primary: Change From Baseline in Eyelash Length at Week 20 — 5.92; 1.10 Millimeter (mm)
Macular Degeneration
Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants
Multiple Myeloma
Primary: Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma — 0 participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 56; 24 percentage of participants
Breast Augmentation · Breast Reconstruction · Revision of Augmentation or Reconstruction
Primary: Local Complications — 18.9; 24.6; 28.7; 6.7 percentage by patient
Prostatic Neoplasms
Primary: Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression — 10; 14; 9; 8 participants
Healthy
Primary: PRISM Chagas Specificity — 23; 16223; 3 participants